EHE registry for rare adult cancers
Part of Cancer clinical trials.
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of epithelioid hemangioendothelioma (a rare type of blood vessel tumor) made on or after December 1, 2023.
- This diagnosis must be confirmed by a doctor who is an expert in sarcomas (cancers of the soft tissues).
- You need a genetic test result showing one of the two gene changes linked to this disease: WWTR1-CAMTA1 or YAP1-TFE3.
- You must be at least 18 years old.
- You must be treated at one of the hospital centers that belongs to the European rare cancer network (EURACAN).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of sirolimus (a targeted therapy) for people with a rare cancer called EHE that is growing or causing symptoms. If you have EHE that can't be removed with surgery and needs treatment, this study may be an option.
This study is a German “registry,” meaning it collects information about people with specific bone or soft tissue tumors (including some borderline or hard-to-classify cases). It helps doctors and researchers learn more about these rare conditions to improve future care.
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
This study is tracking people with a rare blood vessel tumor called epithelioid hemangioendothelioma (EHE) to learn more about how it behaves and how best to care for you. By joining, you'll help doctors improve future treatments for this condition.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
This study is building a registry of people with rare blood diseases. By joining, you help doctors learn more about these conditions and improve future care.
Hear when a new Epithelioid Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.